Mon 11/18/2019 21:02 ET
DJIA28036.2230.840.11%TELCO192.770.230.12%GOLD1470.451.470.10%Shanghai2908.230.870.03%
S&P 5003122.031.560.05%BANKS496.491.290.26%OIL57.000.140.25%BITCOIN8406.58103.401.23%
NASDAQ8549.949.400.11%PHARM571.831.540.27%US/EU1.110.000.00%Futures3121.880.000.00%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - DermTech - DMTK   

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add DMTK
  
From: SunTzu772 (Rep: 1177) reply to SunTzu772Date: 11/07/2019 11:18
Forum: DermTech - Msg #85Thread #674093735 (Rec: 3)
Re: 7.27 8.58 status "E"..key dates to monitor..11/7..11/14..11/21

https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=38050&ver=3&name=373*1%7c374*1%7c378*1%7c375*1%7c379*1%7c376*1%7c380*1%7c377*1%7c381*1&bc=AQAAAgAAAAAA&

https://www.cms.gov/medicare-coverage-database/reports/draft-lcd-status-report.aspx?LCDId=38050&ver=3&name=373*1%7c374*1%7c378*1%7c375*1%7c379*1%7c376*1%7c380*1%7c377*1%7c381*1&bc=AQAAAgAAAAAA&#ResultAnchor

(DL38051)

-----

(EXAS $11 billion mkt cap) Cologuard has a 93% sensitivity rate of detecting cancer.

"Using the DermTech Pigmented Lesion Assay (PLA), RNA gene expression and DNA mutation positivity were evaluated in pigmented lesions concerning for early melanoma. Dr. Jackson found that the addition of TERT mutation status increases the sensitivity of the PLA from 91% to 97%."

https://www.businesswire.com/news/home/20191022005342/en/DermTech-Presents-New-Data-Fall-Clinical-Dermatology

Skin cancer is the #1 most common cancer in US..Colon cancer #3.

https://www.aad.org/media/stats-skin-cancer

-----

https://dermtech.com/press-releases/

http://www.thelion.com/bin/forum.cgi?tf=wall_street_pit&msg=2800776&cmd=r&t=0&dt=1



------------------- "Opportunities multiply as they are seized" -- Sun Tzu circa 500 B.C. -------------------



Reply to SunTzu772 - Msg #82 - 11/05/2019 10:29

7.27 status "E"..key dates to monitor..11/7..11/14..11/21

https://www.cms.gov/medicare-coverage-database/details/lcd-details.aspx?LCDId=38050&ver=3&name=373*1%7c374*1%7c378*1%7c375*1%7c379*1%7c376*1%7c380*1%7c377*1%7c381*1&bc=AQAAAgAAAAAA&

https://www.cms.gov/medicare-coverage-database/reports/draft-lcd-status-report.aspx?LCDId=38050&ver=3&name=373*1%7c374*1%7c378*1%7c375*1%7c379*1%7c376*1%7c380*1%7c377*1%7c381*1&bc=AQAAAgAAAAAA&#ResultAnchor

(DL38051)

-----

(EXAS $11 billion mkt cap) Cologuard has a 93% sensitivity rate of detecting cancer.

"Using the DermTech Pigmented Lesion Assay (PLA), RNA gene expression and DNA mutation positivity were evaluated in pigmented lesions concerning for early melanoma. Dr. Jackson found that the addition of TERT mutation status increases the sensitivity of the PLA from 91% to 97%."

https://www.businesswire.com/news/home/20191022005342/en/DermTech-Presents-New-Data-Fall-Clinical-Dermatology

Skin cancer is the #1 most common cancer in US..Colon cancer #3.

https://www.aad.org/media/stats-skin-cancer

-----

https://dermtech.com/press-releases/

http://www.thelion.com/bin/forum.cgi?tf=wall_street_pit&msg=2800776&cmd=r&t=0&dt=1
What would you like to do? Message: Endorse | Bookmark | Report AbuseUser SunTzu772: Reward | Watch | IgnoreDMTK: Ignore

Msg Top | Msg List | < Prev | Next > | Post New | Reply | Privately | Search | Add DMTK
  

TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.